JenaValve Technology Inc
Funding history
About JenaValve Technology Inc
How much funding has JenaValve Technology Inc raised?
JenaValve Technology Inc has raised $100.4M in total funding. The most recent round was Series C.
Where is JenaValve Technology Inc headquartered?
JenaValve Technology Inc is headquartered in Irvine, CA.
What problem does JenaValve Technology Inc solve?
High-risk patients with severe, symptomatic aortic regurgitation (AR) previously had no FDA-approved transcatheter (minimally invasive) heart valve treatment option, since a transcatheter solution for AR had been considered impossible.
What's JenaValve Technology Inc's solution?
JenaValve's Trilogy Transcatheter Heart Valve System is an FDA-approved TAVR device for aortic regurgitation, using locator technology and a self-expanding nitinol frame to attach securely to native valve leaflets and a purpose-built delivery/introducer system for precise deployment.
What makes JenaValve Technology Inc different?
The page states Trilogy is 'the only TAVR system FDA-approved for aortic regurgitation,' with locator technology that anchors to native leaflets even without calcium, and cites pivotal study data showing 95% technical success and 1.3% valve embolization versus 74-86% success and >12% embolization for off-label TAVR devices.
What makes JenaValve Technology Inc notable?
JenaValve's investors include Bain Capital Life Sciences and the Qatar Investment Authority.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.